Degron-E3 Ligase Recruitment for Selective Protein Degradation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for targeted protein degradation, such as those using thalidomide analogs, have unknown therapeutic mechanisms and limited efficacy in treating various clinical disorders, including cancer and neurodegenerative diseases, due to the lack of specific and efficient protein degradation pathways.

Innovation Solution

Development of compounds (Degrons) that bind to E3 ubiquitin ligases, specifically cereblon, to recruit target proteins for degradation via the ubiquitin-proteasome pathway, using a combination of Targeting Ligands, Degrons, and Linkers to facilitate selective protein degradation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If thalidomide analogs are used for targeted protein degradation, then protein degradation activity is achieved, but the therapeutic mechanism is unknown and efficacy is limited

Engineering Contradiction:

Improvetherapeutic mechanism clarityVSAvoiddegradation pathway specificity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The compound is divided into three functional segments: a targeting ligand that binds to the target protein, a linker that connects the ligand to the degron, and a degron that binds to the E3 ubiquitin ligase. This segmentation allows each component to perform its specific function independently, enabling precise control over the degradation pathway and clarifying the therapeutic mechanism while maintaining modular design flexibility.

Inventive Principle:

Principle #1Segmentation

2Productivity

If traditional degradation methods are used, then some protein degradation is achieved, but efficiency and selectivity are insufficient for treating various clinical disorders

Engineering Contradiction:

Improveprotein degradation efficiencyVSAvoidtarget protein coverage

Core Design Contradiction:

ProductivityVSAdaptability or versatility

Solution Approach 1:

The degron component is designed to bind to a specific E3 ubiquitin ligase family (such as cereblon-containing ligases) that processes multiple different target proteins across various disease contexts. This universal binding capability allows a single degron design to facilitate degradation of diverse target proteins including transcription factors, signaling molecules, and structural proteins, thereby achieving high versatility while maintaining efficient degradation through the conserved ubiquitin-proteasome pathway.

Inventive Principle:

Principle #6Universality (Multi-functionality)

3Adaptability or versatility

If non-druggable proteins are targeted, then new therapeutic opportunities are created, but conventional inhibition methods fail

Engineering Contradiction:

Improvetarget protein accessibilityVSAvoiddrug development complexity

Core Design Contradiction:

Adaptability or versatilityVSEase of manufacture

Solution Approach 1:

Instead of using conventional small molecule inhibitors that rely on blocking active sites or binding pockets (mechanical inhibition), this invention substitutes the degradation mechanism by recruiting the cellular ubiquitin-proteasome system. The compound acts as a molecular bridge that brings the target protein into contact with the E3 ligase, transferring the degradation function from the drug molecule itself to the cell's endogenous degradation machinery, thereby enabling targeting of proteins without druggable sites.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The compounds achieve targeted and efficient degradation of proteins, including those not easily druggable, thereby treating disorders like cancer and neurodegenerative diseases by modulating protein activity.

Implementation Method 1

Covalent attachment of multiple ubiquitin molecules by an E3 ubiquitin ligase to a terminal lysine residue marks the protein for proteasome degradation

Methodology Applied

Scientific EffectUbiquitination: Chemical Bonding